Joel A Sincavage
Supervisory Patent Examiner (ID: 11124, Phone: (571)272-2610 , Office: P/2910 )
Most Active Art Unit | 2911 |
Art Unit(s) | 2911, 2900, 2901, 2910 |
Total Applications | 4082 |
Issued Applications | 4006 |
Pending Applications | 1 |
Abandoned Applications | 75 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 18709533
[patent_doc_number] => 20230332152
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-19
[patent_title] => ANGELMAN SYNDROME ANTISENSE TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/345452
[patent_app_country] => US
[patent_app_date] => 2023-06-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17930
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18345452
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/345452 | ANGELMAN SYNDROME ANTISENSE TREATMENT | Jun 29, 2023 | Pending |
Array
(
[id] => 18893796
[patent_doc_number] => 20240009281
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-11
[patent_title] => MRNA THERAPY FOR POMPE DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/207609
[patent_app_country] => US
[patent_app_date] => 2023-06-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20303
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18207609
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/207609 | MRNA THERAPY FOR POMPE DISEASE | Jun 7, 2023 | Pending |
Array
(
[id] => 18879485
[patent_doc_number] => 20240002854
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-01-04
[patent_title] => Albumin Production and Cell Proliferation
[patent_app_type] => utility
[patent_app_number] => 18/316556
[patent_app_country] => US
[patent_app_date] => 2023-05-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22202
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18316556
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/316556 | Albumin Production and Cell Proliferation | May 11, 2023 | Pending |
Array
(
[id] => 18862320
[patent_doc_number] => 20230416756
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-28
[patent_title] => MODULATION OF GENE EXPRESSION AND SCREENING FOR DEREGULATED PROTEIN EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/299509
[patent_app_country] => US
[patent_app_date] => 2023-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38449
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -36
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18299509
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/299509 | MODULATION OF GENE EXPRESSION AND SCREENING FOR DEREGULATED PROTEIN EXPRESSION | Apr 11, 2023 | |
Array
(
[id] => 18612660
[patent_doc_number] => 20230279392
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => SINGLE-STRANDED RNA-EDITING OLIGONUCLEOTIDES
[patent_app_type] => utility
[patent_app_number] => 18/296912
[patent_app_country] => US
[patent_app_date] => 2023-04-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20234
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18296912
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/296912 | Single-stranded RNA-editing oligonucleotides | Apr 5, 2023 | Issued |
Array
(
[id] => 18451974
[patent_doc_number] => 20230193253
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => Screening artificial nucleic acids by particle display
[patent_app_type] => utility
[patent_app_number] => 18/168066
[patent_app_country] => US
[patent_app_date] => 2023-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14655
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18168066
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/168066 | Screening artificial nucleic acids by particle display | Feb 12, 2023 | Pending |
Array
(
[id] => 19637407
[patent_doc_number] => 12168003
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-17
[patent_title] => Selective inhibition of T follicular helper cells for treatment of autoimmune disorders
[patent_app_type] => utility
[patent_app_number] => 18/165113
[patent_app_country] => US
[patent_app_date] => 2023-02-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 36
[patent_figures_cnt] => 39
[patent_no_of_words] => 23298
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 96
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18165113
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/165113 | SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERS | Feb 5, 2023 | Pending |
Array
(
[id] => 19441421
[patent_doc_number] => 12091662
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => Compositions for modulating tau expression
[patent_app_type] => utility
[patent_app_number] => 18/155945
[patent_app_country] => US
[patent_app_date] => 2023-01-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53793
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18155945
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/155945 | Compositions for modulating tau expression | Jan 17, 2023 | Issued |
Array
(
[id] => 18497717
[patent_doc_number] => 20230220398
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-07-13
[patent_title] => COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION
[patent_app_type] => utility
[patent_app_number] => 18/094128
[patent_app_country] => US
[patent_app_date] => 2023-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57028
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18094128
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/094128 | COMPOSITIONS AND METHODS FOR INHIBITING NUCLEAR RECEPTOR SUBFAMILY 1 GROUP H MEMBER 3 (NR1H3) EXPRESSION | Jan 5, 2023 | Pending |
Array
(
[id] => 18360338
[patent_doc_number] => 20230141929
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-11
[patent_title] => METHOD FOR TREATING CARDIOVASCULAR DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/080049
[patent_app_country] => US
[patent_app_date] => 2022-12-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7470
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18080049
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/080049 | METHOD FOR TREATING CARDIOVASCULAR DISEASE | Dec 12, 2022 | Pending |
Array
(
[id] => 18610849
[patent_doc_number] => 20230277579
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS
[patent_app_type] => utility
[patent_app_number] => 18/055525
[patent_app_country] => US
[patent_app_date] => 2022-11-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25775
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18055525
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/055525 | METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS | Nov 14, 2022 | Pending |
Array
(
[id] => 18308729
[patent_doc_number] => 20230112629
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-04-13
[patent_title] => ANGLEMAN SYNDROME ANTISENSE TREATMENT
[patent_app_type] => utility
[patent_app_number] => 18/055212
[patent_app_country] => US
[patent_app_date] => 2022-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17942
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18055212
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/055212 | Angleman syndrome antisense treatment | Nov 13, 2022 | Issued |
Array
(
[id] => 18375968
[patent_doc_number] => 20230151050
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-05-18
[patent_title] => ANTISENSE NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 18/053679
[patent_app_country] => US
[patent_app_date] => 2022-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16572
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18053679
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/053679 | ANTISENSE NUCLEIC ACIDS | Nov 7, 2022 | Pending |
Array
(
[id] => 18726263
[patent_doc_number] => 20230340531
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-10-26
[patent_title] => METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS
[patent_app_type] => utility
[patent_app_number] => 18/051821
[patent_app_country] => US
[patent_app_date] => 2022-11-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22011
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051821
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/051821 | METHODS AND COMPOSITIONS FOR THE ACTIVATION OF GAMMA-DELTA T-CELLS | Oct 31, 2022 | Pending |
Array
(
[id] => 18436405
[patent_doc_number] => 20230183699
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-15
[patent_title] => AMPHIPHILIC POLYNUCLEOTIDES
[patent_app_type] => utility
[patent_app_number] => 18/051487
[patent_app_country] => US
[patent_app_date] => 2022-10-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13947
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18051487
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/051487 | Amphiphilic polynucleotides | Oct 30, 2022 | Issued |
Array
(
[id] => 19367419
[patent_doc_number] => 12059480
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-13
[patent_title] => Treating metastatic cancer and model systems for metastatic disease
[patent_app_type] => utility
[patent_app_number] => 18/045357
[patent_app_country] => US
[patent_app_date] => 2022-10-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 59
[patent_figures_cnt] => 74
[patent_no_of_words] => 12624
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045357
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/045357 | Treating metastatic cancer and model systems for metastatic disease | Oct 9, 2022 | Issued |
Array
(
[id] => 18141638
[patent_doc_number] => 20230015481
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => MODULATORS AND MODULATION OF THE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS RNA
[patent_app_type] => utility
[patent_app_number] => 17/930364
[patent_app_country] => US
[patent_app_date] => 2022-09-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23984
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930364
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/930364 | Modulators and modulation of the receptor for advanced glycation end-products RNA | Sep 6, 2022 | Issued |
Array
(
[id] => 18842634
[patent_doc_number] => 20230405038
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-12-21
[patent_title] => ANTICANCER COMPOSITIONS AND METHODS FOR MAKING AND USING THEM
[patent_app_type] => utility
[patent_app_number] => 17/895007
[patent_app_country] => US
[patent_app_date] => 2022-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33402
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17895007
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/895007 | Anticancer compositions and methods for making and using them | Aug 23, 2022 | Issued |
Array
(
[id] => 18597578
[patent_doc_number] => 20230272374
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => COMPOSITIONS AND METHODS FOR IDENTIFYING POLYNUCLEOTIDES OF INTEREST
[patent_app_type] => utility
[patent_app_number] => 17/892686
[patent_app_country] => US
[patent_app_date] => 2022-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23590
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17892686
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/892686 | Compositions and methods for identifying polynucleotides of interest | Aug 21, 2022 | Issued |
Array
(
[id] => 18948325
[patent_doc_number] => 11891607
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-02-06
[patent_title] => Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/816084
[patent_app_country] => US
[patent_app_date] => 2022-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20430
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17816084
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/816084 | Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors | Jul 28, 2022 | Issued |